R L Paquette
Affiliation: University of California
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz
University of Michigan, Comprehensive Cancer Center, 1500 E Medical Center Dr, Ann Arbor MI 48109, USA
J Hematol Oncol 6:81. 2013..Interim results of a phase II study of ruxolitinib in myelofibrosis patients with baseline platelet counts of 50-100 × 109/L are reported...
- Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitorsRonald L Paquette
UCLA Department of Medicine, Los Angeles, CA, USA
Cancer Genet 204:392-7. 2011..Inhibition of c-ABL kinase-mediated DNA double-strand repair by TKIs may predispose to EVI1 translocation in this setting...
- Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinibRonald L Paquette
Department of Medicine, UCLA, 42 121 CHS, Los Angeles, CA, USA
Leuk Res 34:708-13. 2010..After three years, no patient developed myelodysplastic syndrome or acute myeloid leukemia...
- Diagnosis and management of aplastic anemia and myelodysplastic syndromeRonald L Paquette
Division of Hematology Oncology, University of California at Los Angeles, 90095 1678, USA
Oncology (Williston Park) 16:153-61. 2002..A wide variety of novel experimental approaches including immunosuppressive therapy, angiogenesis inhibitors, platelet growth factors, and demethylating agents are now under investigation for myelodysplastic syndrome...
- Analysis of c-kit gene integrity in aplastic anemiaR L Paquette
Division of Hematology Oncology, UCLA School of Medicine, USA
Blood Cells Mol Dis 22:159-68. 1996..These results suggest that neither c-kit mutations nor decreased soluble SCF levels are commonly involved in the pathogenesis of acquired AA...
- Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cellsR L Paquette
Department of Medicine, The University of California at Los Angeles, 90095 1678, USA
J Leukoc Biol 64:358-67. 1998..These results demonstrate an important role for IFN-alpha in the generation of DCs with potent antigen-presenting capabilities from peripheral blood monocytes...
- Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancerR L Paquette
Departments of Medicine and Biostatistics, University of California at Los Angeles, Los Angeles, CA, USA
Blood 96:2385-90. 2000..Therefore, ex vivo expanded PBPC are capable of ameliorating posttransplantation neutropenia, thrombocytopenia, and anemia in patients receiving high-dose chemotherapy...
- Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recoveryRonald L Paquette
Department of Medicine, Division of Hematology Oncology, 42 121 UCLA Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
Exp Hematol 30:374-80. 2002..The aim of this study was to evaluate the effect of various ex vivo expansion conditions on the cell products and their ability to accelerate hematopoietic recovery in patients undergoing stem cell transplantation...
- Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivoR L Paquette
UCLA Department of Medicine, Division of Hematology Oncology, Los Angeles, CA 90095 1678, USA
Leukemia 16:1484-9. 2002..The therapeutic activity of IFN-alpha in CML may be due to its ability to stimulate the generation of DCs that can present CML-specific antigens. Resistance to IFN-alpha may result when DC differentiation becomes impaired...
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers
Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
Blood 99:3530-9. 2002..Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs...
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaNeil P Shah
Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Cancer Cell 2:117-25. 2002..Multiple independent mutant clones were detected in a subset of relapsed cases. Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance...
- Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah
Division of Hematology Oncology, University of California, San Francisco School of Medicine, Box 1270, 505 Parnassus Ave, San Francisco, CA 94143, USA
J Clin Oncol 26:3204-12. 2008..Once-daily treatment resulted in less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, a dose- and schedule-optimization study is reported...
- Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyNeil P Shah
Division of Hematology Oncology, Department of Medicine, UCSF School of Medicine, San Francisco, California, USA
J Clin Invest 117:2562-9. 2007....
- Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experienceRita M Braziel
Dept of Pathology, Oregon Health Sciences University, Portland, OR 97201, USA
Blood 100:435-41. 2002..Several patients acquired additional clonal cytogenetic abnormalities during therapy, a finding with significant implications for prognosis and laboratory monitoring in imatinib mesylate-treated CML patients...
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 108:3674-81. 2006..Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity...
- Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorderRyan M O'Connell
Department of Biology, California Institute of Technology, Pasadena, CA 91125, USA
J Exp Med 205:585-94. 2008....